Chief Executive Officer
T-knife
Develops T cell receptor (TCR) engineered T cell therapies (TCR-Ts) that target immunogenic tumor antigens in solid tumors, using fully human TCRs and tailored armoring to enhance T cell signaling and potency. These therapies aim to improve response rates and durability in difficult-to-treat cancer indications, addressing the limitations of current treatments for solid tumors.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$196.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current treatment options for solid tumors often yield unsatisfactory response rates and lack durability. Existing therapies struggle to effectively target and eliminate cancer cells within the complex tumor microenvironment.
Solution
T-knife is developing T cell receptor (TCR) engineered T cell therapies (TCR-Ts) designed to target immunogenic tumor antigens found in solid tumors. The company utilizes fully human TCRs and custom T cell armoring strategies to enhance T cell signaling and potency. These "supercharged" TCR-Ts aim to improve response rates and provide more durable remissions for patients with difficult-to-treat solid tumor cancers. The approach focuses on inducing an optimized immune signaling cascade to stimulate a potent T cell-driven immune response.
Target Audience
The primary target audience includes patients with solid tumors who have limited treatment options, as well as oncologists and medical centers specializing in cancer immunotherapy.
Features
- Fully human TCRs selected for high affinity and specificity against tumor-associated antigens
- Tailored T cell armoring to enhance T cell activation, persistence, and tumor infiltration
- Targeting of immunogenic epitopes to maximize recognition and elimination of cancer cells
- Pipeline of TCR-T candidates for multiple solid tumor indications